Does nattokinase increase stroke risk?

If you take nattokinase for its clot-dissolving power, it is fair to ask whether that same power could tip you toward a stroke rather than away from one.

The short answer: at standard supplement doses, there is no evidence nattokinase increases stroke risk in healthy adults, and its fibrinolytic activity is studied for lowering the risk of clot-driven (ischemic) stroke, the type behind about 87% of all strokes, out of the more than 795,000 strokes Americans have each year. The real concern runs the other way: bleeding, and the rarer hemorrhagic stroke, in specific higher-risk people.

Table of Contents

1. Ischemic vs. Hemorrhagic: Why the Distinction Decides the Answer
2. How Nattokinase Changes the Way Your Blood Clots
3. What Human Safety Studies Actually Show
4. The Documented Cases of Nattokinase and Brain Bleeding
5. Who Should Not Take Nattokinase
6. BioAbsorb Nattokinase: Standard Dose, K2-Free, and Third-Party Tested
7. Frequently Asked Questions
8. Conclusion

1. Ischemic vs. Hemorrhagic: Why the Distinction Decides the Answer

"Does nattokinase increase stroke risk?" cannot be answered honestly until you split "stroke" into its two very different forms. About 87% of strokes are ischemic, caused by a clot blocking blood flow to the brain, while roughly 13% are hemorrhagic, caused by a blood vessel rupturing and bleeding into brain tissue.

That split matters because nattokinase acts on clotting. Its entire reason for being a cardiovascular supplement is that it breaks down fibrin, the mesh that holds clots together, which is relevant to the ischemic side of the ledger. The flip side is that anything nudging blood away from clotting can, in the wrong person, nudge it toward bleeding, the hemorrhagic side. Hemorrhagic strokes are less common but carry the highest mortality of any stroke type and can be driven by anticoagulation-related bleeding.

So the accurate framing is two answers in one. For clot-driven stroke, nattokinase's effect points toward protection rather than harm. For bleeding-driven stroke, there is a real theoretical concern, and the practical question becomes who is vulnerable to it. High blood pressure is the leading cause of hemorrhagic stroke, and the American Stroke Association estimates about 80% of strokes are preventable by managing exactly these kinds of risk factors. (This article tackles the risk side of the question. For the other side, whether nattokinase may help prevent clot-driven stroke, see our companion review of the prevention evidence.)

2. How Nattokinase Changes the Way Your Blood Clots

Nattokinase is a fibrinolytic enzyme derived from natto, the fermented soybean food, and our complete guide to nattokinase covers its origins and mechanism in depth. In practical terms it works on several clotting pathways at once: it directly breaks down fibrin, it inhibits plasminogen activator inhibitor-1 (PAI-1), and it supports the body's own clot-clearing activity.

It also shifts the raw materials of clotting. According to Memorial Sloan Kettering's herb database, nattokinase decreases plasma fibrinogen, factor VII, and factor VIII, three components that push blood toward clotting. Lowering them is helpful if your problem is excess clotting; it is the mechanism behind the bleeding concern if your problem is bleeding.

Importantly, in a single-dose study of healthy young men, the boost in fibrinolysis after oral nattokinase stayed within the normal physiological range. That is the crux of the safety story: at ordinary doses in ordinary people the effect is modest. It becomes clinically meaningful mainly when it is amplified, by a much higher dose, by another blood-thinning agent, or by a body already prone to bleeding.

3. What Human Safety Studies Actually Show

The trial evidence is broadly reassuring at studied doses. The USC-led Nattokinase Atherothrombotic Prevention Study followed 265 adults (median age 65) for about three years on 2,000 FU daily and found no significant difference in adverse events versus placebo. Notably, it also found no benefit on artery-plaque progression, so this is honest data rather than marketing. A 2023 meta-analysis of 6 randomized trials and 546 participants likewise reported no notable adverse events.

Real-world use points the same direction. A 2023 observational report tracking patients with vascular disease found the rate of cerebral and cardiac complications in the nattokinase group essentially matched the control group, at about 6.98% versus 6.35%.

But there is a ceiling on what these studies can tell you. Trials deliberately exclude high-risk patients, run for months rather than years, and pool only a few hundred people, with the largest of these gathering just 546 participants, too few to reliably catch a rare event. No published case series has systematically documented nattokinase-associated bleeding, which means the reassurance applies to the populations studied, not necessarily to the vulnerable individuals those trials screened out.

4. The Documented Cases of Nattokinase and Brain Bleeding

The single most relevant piece of evidence for this question is a 2008 case report in the journal Internal Medicine. A patient taking aspirin for secondary stroke prevention developed an acute cerebellar hemorrhage after taking nattokinase 400 mg daily for seven days, with multiple cerebral microbleeds visible on MRI. The authors concluded that nattokinase may raise the risk of intracerebral hemorrhage specifically in people who have bleeding-prone small-vessel disease and are already taking another antithrombotic agent.

Three details make this case a map of where the danger actually lives rather than a reason for blanket alarm. The dose was 400 mg, four times the standard 100 mg of a typical supplement. The patient was simultaneously taking aspirin, a second blood-thinning agent. And the pre-existing microbleeds signalled fragile brain vessels before nattokinase entered the picture. It was a stack of risk factors, not standard-dose use in a healthy adult.

It is not the only serious report. Memorial Sloan Kettering also references a fatal hemoperitoneum, a fatal abdominal bleed, in an older adult using over-the-counter nattokinase for atrial fibrillation. These are isolated case reports across two decades of use, not a pattern of population-level harm, but they are real, and they define the exact conditions under which caution is non-negotiable.

5. Who Should Not Take Nattokinase

Because the risk is about bleeding, the people who should avoid nattokinase, or use it only with a doctor's sign-off, are those whose bleeding risk is already elevated. High blood pressure deserves special mention: it is the leading cause of hemorrhagic stroke, which accounts for roughly 13% of all strokes, so uncontrolled hypertension is a meaningful red flag.

Talk to your physician before taking nattokinase if you:

• Take prescription anticoagulants (warfarin, apixaban, rivaroxaban) or antiplatelet drugs (aspirin, clopidogrel), the combination that has been linked to intracerebral hemorrhage
• Have a bleeding or clotting disorder, or a low platelet count
• Have uncontrolled high blood pressure, or a history of hemorrhagic stroke or cerebral microbleeds
• Are scheduled for surgery within about two weeks (most guidance is to stop at least 14 days before a procedure)
• Are pregnant or nursing, as safety data in these groups is absent

One easily missed scenario is supplement stacking. Several common supplements, including turmeric, fish oil, and ginkgo, have mild blood-thinning effects of their own, so combining them with nattokinase can add up; our guide on taking turmeric and nattokinase together walks through how to do it sensibly. When in doubt, the standard clinically studied 100 mg / 2,000 FU dose is the ceiling to respect, and the nattokinase dosage guide covers the specifics.

6. BioAbsorb Nattokinase: Standard Dose, K2-Free, and Third-Party Tested

The safest way to use nattokinase is at the dose the research actually studied, in a form you can trust. BioAbsorb Nattokinase Enzyme delivers 100 mg (2,000 FU) per capsule, the standard clinically studied dose and a fraction of the 400 mg amount involved in the hemorrhage case report. Each batch is third-party tested for potency (at least 2,000 FU), heavy metals, and microbial contaminants, so what the label says is what the capsule delivers.

Two design choices matter for a bleeding-sensitive supplement. First, it uses DRcaps delayed-release capsules, which protect the enzyme from stomach acid without the phthalates and plasticizers found in some enteric coatings, rather than any liposomal claim. Second, it is intentionally free of vitamin K2. That is relevant here because natto food is naturally rich in vitamin K, which promotes clotting and partially offsets nattokinase's blood-thinning effect, whereas a purified, K2-free supplement is not buffered the same way. For someone managing K2 intake that is a deliberate advantage; for someone on warfarin it is exactly the kind of detail a prescriber needs to know.

Manufactured in a Canadian GMP-certified facility, it is non-GMO and free of gluten, nuts, dairy, and all animal products. None of that changes the core message: it is a sound choice for a healthy adult using it appropriately, and not a substitute for medical advice if any of the cautions above apply to you.

Frequently Asked Questions

Can nattokinase cause a stroke?

In healthy adults at standard doses there is no evidence it does, and its clot-dissolving action is studied for lowering ischemic-stroke risk. The documented danger is hemorrhagic stroke, or brain bleeding, in specific high-risk contexts, such as a 2008 case of cerebellar hemorrhage in someone taking a high dose alongside aspirin with pre-existing microbleeds.

Is nattokinase safe if I have already had a stroke?

Talk to your doctor before considering it, because a prior hemorrhagic stroke is a specific red flag and people with a stroke history often have fragile brain vessels that raise bleeding risk. Memorial Sloan Kettering flags increased intracerebral-hemorrhage risk when nattokinase is combined with antithrombotic drugs, which many stroke survivors take.

Does nattokinase thin your blood too much?

At standard doses in trials, no, and a three-year study of 265 adults found no significant excess of adverse events. The problem is an additive effect: stacking nattokinase on top of prescription blood thinners or aspirin is where bleeding risk becomes clinically meaningful.

Can I take nattokinase with aspirin or warfarin?

Not without medical supervision, because both combinations increase bleeding risk and the aspirin combination specifically has been linked to a brain bleed in a vulnerable patient. If you take any anticoagulant or antiplatelet, your prescriber needs to weigh in first.

What dose of nattokinase is dangerous?

There is no established toxic dose, but the documented hemorrhage case involved 400 mg daily, four times the standard 100 mg / 2,000 FU supplement amount, combined with other risk factors. Staying at the clinically studied dose and avoiding blood-thinner stacking is the sensible approach.

Is the bleeding risk different for natto food versus supplements?

Possibly, because natto food is rich in vitamin K, which promotes clotting and may partially offset nattokinase's blood-thinning effect, whereas purified supplements remove that vitamin K so the enzyme's effect is not buffered the same way. For people on warfarin that vitamin-K difference cuts the other way and is worth discussing with a doctor.

Conclusion

For a healthy adult at the standard 2,000 FU dose, the evidence does not show nattokinase increasing stroke risk; the genuine concern is bleeding and the rare hemorrhagic stroke, and it is concentrated in a definable group of people on blood thinners, with bleeding disorders, uncontrolled high blood pressure, or a prior brain bleed. If that is not you, a standard-dose, K2-free, third-party-tested nattokinase used as directed is a reasonable choice; if it is you, the honest answer is to clear it with your doctor first. Either way, the safest use of nattokinase starts with knowing which side of that line you are on.

Research References

1. Cerebellar Hemorrhage Provoked by Combined Use of Nattokinase and Aspirin in a Patient with Cerebral Microbleeds. Internal Medicine, Vol. 47 (2008). Case report of an acute cerebellar hemorrhage after high-dose nattokinase (400 mg/day) combined with aspirin in a patient with pre-existing cerebral microbleeds, supporting the article's central point that risk is concentrated in bleeding-prone, antithrombotic-treated patients.
2. Nattokinase Atherothrombotic Prevention Study: A Randomized Controlled Trial. Clinical Hemorheology and Microcirculation, Vol. 78 (2021). Randomized trial of 265 adults on 2,000 FU for about three years; found no significant difference in adverse events versus placebo and a null effect on subclinical atherosclerosis, cited for long-term safety at the standard dose.
3. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24(8) (2023). Pooled 6 randomized trials and 546 participants, reporting no notable adverse events, cited for the trial-level safety signal at studied doses.
4. Understanding the Concept of Nattokinase Use: A Few Years After Beginning. Biotechnology & Biotechnological Equipment (2023). Observational data in patients with vascular disease showing cerebral and cardiac complication rates in the nattokinase group similar to controls (about 6.98% vs 6.35%).
5. Nattokinase, About Herbs Database. Memorial Sloan Kettering Cancer Center (2022). Institutional summary noting theoretical increased bleeding and intracerebral-hemorrhage risk with anticoagulant, antiplatelet, and fibrinolytic drugs, a fatal hemoperitoneum case, the fibrinogen/factor VII/factor VIII mechanism, and natto's vitamin K content.
6. Types of Stroke. Johns Hopkins Medicine. Reference for the ischemic (about 87%) versus hemorrhagic (about 13%) breakdown of strokes.
7. Stroke Facts. Centers for Disease Control and Prevention. Source for U.S. stroke burden (more than 795,000 strokes per year).
8. Types of Stroke and Treatment. American Stroke Association. Reference for high blood pressure as the leading cause of hemorrhagic stroke and for the estimate that roughly 80% of strokes are preventable.
9. Hemorrhagic Stroke. StatPearls, NCBI Bookshelf. Reference for hemorrhagic stroke representing roughly 10 to 15% of strokes, carrying the highest mortality, and being linked to anticoagulation-related coagulopathy.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.